Amicus Therapeutics

Bewertungs-Analyse

Über das Unternehmen

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Ga

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich Amicus Therapeutics kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.